Lessons from the Fenfluramines: Antiobesity Medications are Frequently Misused

Lawless C Force RW . Survey of the appropriateness of prescribing and the use of anti-obesity medications. In: Proceedings of the ACCP Spring Practice and Research Forum, Palm Springs, CA, April 7, 1998.

Package information. Redux (dexfenfluramine HCl). Philadelphia: Wyeth-Ayerst Laboratories, April 1996.

Package information. Meridia (sibutramine HCl). Mt. Olive, NJ: Knoll Pharmaceuticals, November 1997.

Package information. Xenical (orlistat). Nutley, NJ: Roche Laboratories, April 1999.

US Department of Health and Human Services. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations. MMWR Morb Mortal Wkly Rep 1997;46:1061–6.

Wee CC Phillips RS Aurigemma G Erban S Kriegal G Riley M Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med 1998;129:870–4.